Annexon reports fourth quarter and year-end 2023 financial results and key anticipated milestones

Pivotal phase 3 data for anx005 in guillain-barrÉ syndrome (gbs) expected in second quarter 2024 initiation of pivotal phase 3 anx007 archer ii trial in geographic atrophy (ga) expected in mid-2024, a global sham-controlled trial using vision preservation as primary outcome measure clinical proof-of-concept data with anx1502 oral inhibitor of the classical pathway expected in second half of 2024 robust balance sheet with cash, cash equivalents, and short-term investments of approximately $260 million as of december 31, 2023, and anticipated runway into mid-2026 brisbane, calif., march 26, 2024 (globe newswire) -- annexon, inc. (nasdaq: annx), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today highlighted portfolio progress and reported fourth quarter and full year 2023 financial results.
ANNX Ratings Summary
ANNX Quant Ranking